The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

This study is testing a CAR-T cell therapy called BRL-201 — where a patient's own immune cells are modified in the lab to target and destroy cancer cells — in people with relapsed or refractory B-cell non-Hodgkin lymphoma (a type of blood cancer that has come back or stopped responding to prior treatments). **You may be eligible if...** - You are 18 years old or older - You have been confirmed to have aggressive B-cell non-Hodgkin lymphoma that expresses the CD19 protein - Your cancer has relapsed (come back) or is refractory (not responding to treatment) after adequate prior therapy - You have at least one measurable tumor - Your general health is good (ECOG score 0–1), and your heart and lung function are adequate - Your estimated survival is at least 3 months - There is no evidence of the cancer spreading to the brain or spinal fluid **You may NOT be eligible if...** - Your cancer has spread to the central nervous system (brain/spine) - You have severe heart, lung, or other organ problems - Your prior cancer treatments have left you with significant ongoing side effects Talk to your doctor to see if this trial is right for you.